Test Price
2,800 AED✅ Home Collection Available
SLC25A19 Gene (Thiamine Metabolism Dysfunction Syndrome 4, Progressive Polyneuropathy Type) Genetic Test in UAE | 2800 AED | 2026 DHA Guidelines
تحليل جين SLC25A19 (متلازمة خلل استقلاب الثيامين النوع 4 – الاعتلال العصبي المحيطي المترقي) بتقنية NGS في الإمارات | 2800 درهم | إرشادات هيئة الصحة بدبي 2026
99.9% Diagnostic Sensitivity – ISO 9001:2015 Certified Lab (INT/EGQ/2509DA/3139); Sanger‑confirmed NGS results.
Premium Logistics – Paid Hospital‑Grade Home Collection via ISO‑Certified Cold‑Chain Phlebotomy (8 AM–11 PM).
Clinical Guidance – Telephonic Post‑Test Clinical Guidance with DHA‑Licensed Genetic Counsellor.
Direct Billing Verification – Confirm Insurance Coverage via WhatsApp +971 54 548 8731.
دقة تشخيصية 99.9% | خدمة منزلية متطورة | استشارة طبية هاتفية بعد الفحص | دعم مباشر عبر الواتساب
Overview
This comprehensive Next‑Generation Sequencing (NGS) test analyses the entire coding region of the SLC25A19 gene to identify pathogenic variants responsible for Thiamine Metabolism Dysfunction Syndrome 4 (progressive polyneuropathy type), a rare inherited neuropathy. The test provides definitive molecular confirmation for suspected hereditary peripheral neuropathy, enabling personalized management and family planning in compliance with UAE genetic testing regulations.
يفحص هذا الاختبار الجين SLC25A19 بتقنية التسلسل الجيني الشامل لتأكيد الطفرات المسببة لمتلازمة خلل استقلاب الثيامين النوع 4، مما يدعم التشخيص الدقيق للاعتلال العصبي الوراثي وخطط العلاج والوقاية الأسرية.
| Feature | Our Test – SLC25A19 NGS | Closest Alternative – Single‑Gene Sanger |
|---|---|---|
| Precision | Full‑gene coverage with >50x mean depth; Sanger validation of all variants | Targeted exon sequencing only; may miss deep intronic or copy‑number changes |
| Methodology | Illumina‑based NGS + bioinformatics pipeline conforming to ACMG 2026 guidelines | Capillary electrophoresis; manual analysis |
| Turnaround Time | 3–4 Weeks from sample receipt | 4–6 Weeks typically |
| UAE Regulatory Compliance | DHA-licensed lab, ISO 9001, full PDPL & Federal Decree-Law No. 41/2024 adherence | Variable; often lacks DHA certification |
Physician Insight & Safety Protocol
“A genetic diagnosis is not merely a laboratory report—it is a guiding map for families facing progressive neuropathy. While this test identifies pathogenic variants in SLC25A19 with exceptional accuracy, the result must always be correlated with a complete neurological evaluation. I urge every patient to maintain their current treatment plan and never discontinue prescribed medication without direct consultation.”
— Dr. Prabhakar Reddy, DHA License No. 61713011
Pre‑Test Exclusion Criteria & Emergency Red Flags
- Exclusion Criteria: Active febrile illness, haemodynamic instability, or inability to provide written informed consent. Genetic testing of minors requires court‑approved parental consent under UAE CDS Law 2026.
- Potential Red Flags: Sudden onset of seizures, acute respiratory distress, or rapid neurological deterioration. If these occur, seek immediate emergency care; do not delay for test collection.
- Sample Integrity: Whole blood must be drawn in EDTA tubes; Dried Blood Spots on FTA cards must be completely air‑dried before packaging. A dedicated genetic counselling session and a three‑generation pedigree chart are mandatory prior to testing, as per DHA/MOHAP guidelines.
Patient FAQ & Clinical Guidance
Q1. What does the SLC25A19 genetic test detect and who should consider it?
The SLC25A19 NGS test definitively identifies mutations responsible for thiamine metabolism dysfunction syndrome 4 with progressive polyneuropathy, offering a conclusive molecular diagnosis for patients—especially children—presenting with unexplained sensory‑motor neuropathy, ataxia, or episodic encephalopathy. It is indicated when clinical and neurophysiological findings suggest a hereditary metabolic neuropathy, or for carrier screening in families with a known mutation. يكشف طفرات الجين SLC25A19 المسببة للاعتلال العصبي المترقي، ويساعد في التشخيص المبكر وفي فحص الحاملين للمرض في العائلات المعرضة للخطر.
Q2. How is the test performed and when will I receive the results?
A single blood draw, extracted DNA sample, or a dried blood spot on an FTA card is collected by our certified phlebotomist at your home, and using Next‑Generation Sequencing technology, your detailed report is delivered in 3 to 4 weeks. The process includes pre‑test genetic counselling, thorough quality control, and Sanger confirmation of any clinically significant variant before the final report is released. يتم سحب عينة في المنزل أو تقديم بقعة دم جافة، وتصدر النتيجة الكاملة بعد ٣-٤ أسابيع تتضمن تأكيداً دقيقاً للنتائج.
Q3. Is genetic counselling required and how is my DNA data protected under UAE law?
Yes, pre‑ and post‑ genetic counselling are mandatory under DHA regulations; your DNA data is safeguarded by Federal Decree‑Law No. 41 of 2024 (Art. 87) and the UAE Personal Data Protection Law (PDPL), ensuring it is never shared without explicit consent. All testing is performed in our ISO 9001:2015 accredited facility, with full transparency regarding variant interpretation and incidental findings. الاستشارة الوراثية إلزامية قبل وبعد الفحص، ويتم حماية بيانات الحمض النووي بموجب المرسوم الاتحادي رقم ٤١ لسنة ٢٠٢٤ وقانون حماية البيانات الشخصية الإماراتي.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians